A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy
Public ClinicalTrials.gov record NCT02141282. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy
Study identification
- NCT ID
- NCT02141282
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- AbbVie
- Industry
- Enrollment
- 127 participants
Conditions and interventions
Conditions
Interventions
- Venetoclax Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 99 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 9, 2014
- Primary completion
- Dec 21, 2021
- Completion
- Dec 21, 2021
- Last update posted
- Dec 18, 2022
2014 – 2021
United States locations
- U.S. sites
- 15
- U.S. states
- 10
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Moores Cancer Center at UC San Diego /ID# 128535 | La Jolla | California | 92093 | — |
| University of California, Los Angeles /ID# 127262 | Los Angeles | California | 90095 | — |
| Stanford University School of Med /ID# 126495 | Stanford | California | 94305-2200 | — |
| Georgetown University Hospital /ID# 127261 | Washington D.C. | District of Columbia | 20007 | — |
| Emory Midtown Infectious Disease Clinic /ID# 131249 | Atlanta | Georgia | 30322 | — |
| Northwestern University Feinberg School of Medicine /ID# 126497 | Chicago | Illinois | 60611-2927 | — |
| Beth Israel Deaconess Medical Center /ID# 134509 | Boston | Massachusetts | 02215-5400 | — |
| Dana-Farber Cancer Institute /ID# 126496 | Boston | Massachusetts | 02215 | — |
| Columbia Univ Medical Center /ID# 128536 | New York | New York | 10032-3725 | — |
| New York Presbyterian Hospital Weill Cornell Medical Center /ID# 129648 | New York | New York | 10032-3725 | — |
| Univ Rochester Med Ctr /ID# 130011 | Rochester | New York | 14642 | — |
| The Ohio State University /ID# 127263 | Columbus | Ohio | 43210 | — |
| University of Pennsylvania /ID# 126860 | Philadelphia | Pennsylvania | 19104-5502 | — |
| University of Texas MD Anderson Cancer Center /ID# 126498 | Houston | Texas | 77030 | — |
| University of Utah /ID# 130813 | Salt Lake City | Utah | 84112-5500 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02141282, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 18, 2022 · Synced May 12, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02141282 live on ClinicalTrials.gov.